Shanghai Pharmaceuticals Holding (SHA:601607, HKG:2607) received approval from Malaysia's pharmaceutical regulator to market Rivaroxaban tablets in the country, according to a Shanghai bourse filing on Wednesday.
The drug is used to treat patients with non-valvular atrial fibrillation, deep vein thrombosis, and pulmonary embolism, as well as to prevent venous thromboembolism.